Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T22136 |
PRL-3 Inhibitor I
PRL-3 Inhibitor,BR-1 |
Phosphatase; Others | Metabolism; Others |
PRL-3 Inhibitor I (BR-1) 是 PRL-3 抑制剂,IC50=0.9 μM。它在细胞检测中显示降低侵袭性。 | |||
T9855 |
BR102910
4-Thiazolecarboxamide, N-[2-[(2S)-2-cyano-4,4-difluoro-1-pyrrolidinyl]-2-oxoethyl]-2-[(3,4-dichlorophenyl)methyl]- |
Others | Others |
BR102910 (4-Thiazolecarboxamide, N-[2-[(2S)-2-cyano-4,4-difluoro-1-pyrrolidinyl]-2-oxoethyl]-2-[(3,4-dichlorophenyl)methyl]-) 是一种选择性的成纤维细胞活化蛋白(FAP)的抑制剂。 | |||
T7156 |
NIBR189
|
EBI2/GPR183 | GPCR/G Protein |
NIBR189是 EBI2(GPR183)小分子拮抗剂(IC50:11 nM)。 | |||
T10596 |
BR102375
|
Others | Others |
BR102375 is a non-TZD PPAR γ full agonist (EC50: 0.28 μM) for the treatment of type 2 diabetes. | |||
T70659 | BR103 | ||
BR103 is a C3aR-selective agonist that is metabolically stable. | |||
T13138 |
TGFBR1-IN-1
|
ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM). | |||
T69603 |
BR103354
|
||
BR103354 is a novel fibroblast activation protein (FAP) inhibitor with anti-diabetic and anti-steatotic effects. BR103354 inhibited FAP with an IC50 value of 14 nM, showing high selectivity against dipeptidyl peptidase (DPP)-related enzymes and prolyl oligopeptidase (PREP). BR103354 exhibited good pharmacokinetic properties as evidenced by oral bioavailability of 48.4% and minimal hERG inhibition. Single co-administration of BR103354 with hFGF21 reduced nonfasting blood glucose concentrations, i... |